Oncoclínicas do Brasil Serviços Médicos (ONCO3) Q2 2025 earnings summary

Executive summary

• The company is undergoing a commercial and operational transition, phasing out contracts with high delinquency payors and discontinuing low-margin contracts, while optimizing headcount by approximately 400 since Q3 2024 and reviewing non-core assets.

• Revenue remained flat sequentially in Q2 2025 as contract exits offset growth with other clients, with the exit from Unimed FERJ to impact future quarters.

• Adjusted EBITDA rebounded 38.3% quarter-over-quarter, with margin expansion despite lower net revenues.

• Net loss of BRL 136.8 million (R$136.8 million) in Q2 2025, impacted by commercial and operational factors and high financial expenses.

• Cash flow consumption increased, mainly due to client delinquency, high interest expenses, and growth capex.

Financial highlights

• Gross revenue in Q2 2025 was R$1,657.6 million, stable sequentially but down 3.8% year-over-year; LTM gross revenue reached R$6.8 billion, up 4.9% YoY.

• Net revenue declined 1.9% sequentially in Q2 2025 due to higher doubtful receivables and provisions, totaling R$1,464.4 million.

• Adjusted EBITDA reached R$185.1 million (12.6% margin), up 38.3% sequentially but down 41.7% year-over-year.

• Cash gross margin improved 250 bps sequentially to 30.3%, but declined 360 bps year-over-year.

• Negative operational cash flow of BRL 196.1 million, mainly from late payments by discontinued clients.

Outlook and guidance

• Sequential revenue deceleration is expected in Q3 2025 due to the end of services for Unimed and Unifers starting August.

• Medium-term growth is anticipated from new contracts, client base recycling, and margin recovery, with new cancer centers and medical facilities to be inaugurated.

• Capex plan and non-core hospital operations are under strategic review and reprioritization.